News & Press Releases

Access the latest news about Lipidor, our current projects, publications and collaborations. Thank you for your interest in Lipidor!

Subscribe

January 24, 2024

Lipidor completes SEK 1.7 million sale of animal segment patent

STOCKHOLM, Sweden, 24th January 2024 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that one of the company's patents, previously out-licensed to Emollivet AB, has now been sold to the same party. The sale is aimed at strengthening Lipidor's short term cash position. Since its inception…

December 17, 2019

Lipidor AB (publ) updates timetable for results from ongoing phase III study – marginal shift in results reporting

Lipidor AB (Nasdaq First North: LIPI) today announces that results from the ongoing phase-III study, of calcipotriol spray against mild to moderate…

December 10, 2019

Lipidor (Nasdaq First North: LIPI) and Cannassure (TASE:CSURE) enter a feasibility study and licence option agreement for development and sales of topical medical cannabis products

Lipidor AB (“Lipidor”), a Swedish topical drug development company, and Cannassure Therapeutics Ltd (“Cannassure”), an Israel based developer and producer of innovative…

November 21, 2019

Correction: Lipidor AB (publ) publishes interim report for Q3 2019

The correction relates to the non-attached interim report for Q3 in the press release and the incorrect link to the interim report…

November 21, 2019

Lipidor AB (publ) publishes interim report for Q3 2019

Statement from Lipidor’s CEO Lipidor is experiencing considerable interest from both investors and the pharma industry, and in many meetings during the…

November 7, 2019

Lipidor Announces Last Patient Out in Calcipotriol/AKVANO spray (AKP01) Phase III Study Targeting Psoriasis

Lipidor AB (publ) today reports that the last patient has completed treatment in the phase III study evaluating the efficacy of using…

September 23, 2019

Lipidor has been approved for listing on the Nasdaq First North Growth Market with first day of trading on September 27, 2019

Nasdaq Stockholm AB today approved the application of Lipidor AB ("Lipidor" or "the Company") for admission to trading of Lipidor shares and…

September 16, 2019

Lipidor’s New Share Issue Achieves 540 % Subscription

On Friday, 13 September 2019, the subscription period ended for Lipidor AB's ("the Company") issuance of units before the Company’s planned listing…

September 9, 2019

Lipidor Announces Enrolment of Last Patient in Calcipotriol/AKVANO spray (AKP01) Phase III Study Targeting Psoriasis

Lipidor AB (publ) today reports that the last patient has been enrolled in the ongoing phase III study using calcipotriol spray against…

August 27, 2019

Lipidor AB publishes Information Memorandum in connection with a new issue of SEK 25.2 million prior to listing on Nasdaq First North Growth Market [updated]

The Board of Directors of Lipidor AB ("Lipidor" or "the Company") has decided to carry out a new issue of a maximum…

August 26, 2019

Lipidor AB publishes Information Memorandum in connection with a new issue of SEK 25.2 million prior to listing on Nasdaq First North Growth Market

The Board of Directors of Lipidor AB ("Lipidor" or "the Company") has decided to carry out a new issue of a maximum…